Stewart-Feder: Reassignment Is A Moral--Not An Administrative--Matter

Editor's Note: Scientists Walter Stewart, 48, and Ned Feder, 65, have been working side by side at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) in Bethesda, Md., since the late 1960s. Their employment agreements with NIDDK once required that they spend 80 percent of their time on health- related lab research and 20 percent on their investigations of scientific fraud and misconduct. However, their renown in the international science community stems virtually 100

Written byWalter Stewart
| 9 min read

Register for free to listen to this article
Listen with Speechify
0:00
9:00
Share

Editor's Note: Scientists Walter Stewart, 48, and Ned Feder, 65, have been working side by side at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) in Bethesda, Md., since the late 1960s. Their employment agreements with NIDDK once required that they spend 80 percent of their time on health- related lab research and 20 percent on their investigations of scientific fraud and misconduct. However, their renown in the international science community stems virtually 100 percent from their work in the latter category.

Most prominent among their forays into what's become known as fraud-busting are cases that arose in the early and mid-1980s involving scientists John Darsee, a Harvard University cardiologist, and David Baltimore, a Nobel Prize-winning immunologist. In the first instance, Stewart and Feder found--and subsequently documented in a published article (Nature, 325:207, Jan. 15, 1987)--that some of Darsee's coauthors on a paper had, to use Stewart ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies